On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-65.
The decision to discontinue this study is part of a strategic reprioritization of the company's Communicable Diseases research and development (R&D) portfolio. No safety issues were identified.
Efficacy data from the Phase 2 field study will be available once the final data analyses, which are now underway, are complete.
Also Read: Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug.
Mosnodenvir (formerly JNJ-1802) was shown to be safe and well tolerated in previous Phase 1 and Phase 2a clinical studies.
In October 2023, results from the Phase 2a human challenge study found that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo.
The study evaluated different dosing regimens – low, medium or high – of JNJ-1802 against an attenuated dengue 3 serotype (DENV-3) in healthy adults.
All participants received daily doses of JNJ-1802 or a placebo over 26 days, during which they were challenged with DENV-3 on day 5.
All participants were monitored over 85 days. The study found a dose-dependent antiviral effect on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA compared to placebo and was safe and well-tolerated.
In May, Takeda Pharmaceutical Co Ltd's (NYSE:TAK) dengue vaccine received World Health Organization's (WHO) prequalification.
TAK-003 is the second dengue vaccine to be prequalified by WHO.
WHO recommended using TAK-003 in children aged 6–16 in settings with high dengue burden and transmission intensity.
Price Action: JNJ stock is down 0.60% at $159.53 at the last check on Friday.
- Lucid Air Electric Vehicles Join Blink Charging's Envoy Program: Details.
Photo via Shutterstock
